Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antigen specific active immunotherapy: lessons from the first decade.

Michel Adamina1, Daniel Oertli

  • 1Institute of Surgical Research and Hospital Management, University Hospital Basel, Switzerland. madamina@uhbs.ch

Swiss Medical Weekly
|June 23, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment.

Journal of Crohn's & colitis·2026
Same author

Using large language models to integrate international IBD guidelines: A retrieval-augmented generation approach.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2026
Same author

Fluorescence-guided ureter mapping in colorectal surgery: a systematic review of intraureteral ICG and emerging renal fluorophores.

Frontiers in surgery·2026
Same author

Outcomes of damage control surgery in perforated sigmoid diverticulitis: a comparison before and after implementing a new treatment algorithm.

Updates in surgery·2026
Same author

Early evaluation of the low anterior resection syndrome after sphincter sparing rectal cancer surgery and prompt treatment: a cohort study protocol.

International journal of colorectal disease·2026
Same author

Correction: EAES, ESCP, and ESGAR clinical practice guideline update on taTME for rectal cancer.

Surgical endoscopy·2026
Same journal

Metamizole-induced agranulocytosis: utilisation trends, pharmacovigilance signals and regulatory risk-minimisation in Switzerland.

Swiss medical weekly·2026
Same journal

Female genital mutilation/cutting and risk of obstetric anal sphincter injury at delivery.

Swiss medical weekly·2026
Same journal

Drug prescription before and after implementation of a CPOE system on the Paediatric Intensive Care Unit: a quality improvement study.

Swiss medical weekly·2026
Same journal

Trends in health- and lifestyle-related aspects in women of childbearing age: analysis of Swiss Health Survey data between 1992 and 2022.

Swiss medical weekly·2026
Same journal

Microplastics in the air and potential health risks - a narrative review.

Swiss medical weekly·2026
Same journal

Potentially inappropriate medication: prevalence, risk of hospitalisation and associated healthcare costs in the general older population of Switzerland.

Swiss medical weekly·2026
See all related articles

Malignant melanoma immunotherapy has advanced significantly since 1991 with antigen-specific strategies. Ongoing research aims to improve immune responses for better melanoma treatment outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Malignant melanoma incidence is rising, with limited metastatic treatment options.
  • Melanoma is known for its immunogenicity, prompting research into immunotherapy for decades.
  • The molecular characterization of melanoma antigens in 1991 marked a pivotal moment for active immunotherapy.

Purpose of the Study:

  • To provide an overview of melanoma immunotherapy technologies and progress since 1991.
  • To explore advancements in antigen-specific active immunotherapy for metastatic melanoma.
  • To propose future research directions for enhancing anti-melanoma immune responses.

Main Methods:

  • Review of technologies used in melanoma immunotherapy.
  • Analysis of clinical immunization protocols and strategies.

Related Experiment Videos

  • Examination of molecular characterization of melanoma-associated antigens.

    • Main Results:

    • Significant progress in antigen-specific active immunotherapy since 1991.
    • Development of immunization strategies in the adjuvant setting for metastatic melanoma.
    • Molecular characterization enables monitoring of immune responses.

    Conclusions:

    • Melanoma immunotherapy has evolved, with antigen-specific approaches showing promise.
    • Refinements are ongoing to maximize the potential of active immunotherapy.
    • Further basic and translational research is needed to induce clinically relevant immune responses against melanoma.